KYVERNA THERAPEUTICS, INC.

Lobbying client · California · filed 2025 to 2026

Biopharmaceutical company focused on developing cell therapies for autoimmune diseases.

$170,000 Reported spend

4 Filings counted

1 Firms hired

1 Bills named

Spend is reported income plus in-house expenses across 4 filings. Everything on this page is grouped by the client's LDA id (69525), not by name.

Firms hired 1

AKIN GUMP STRAUSS HAUER & FELD $170,000 4 filings

Bills named in these filings 1

HR 8646
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027

1 filing

Reported by year 2 years

2026 $120,000 2 filings
2025 $50,000 2 filings

Issues lobbied 1

Health Issues 4

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 2

HOUSE OF REPRESENTATIVES 3
SENATE 3

Recent filings 4 total

Q2

AKIN GUMP STRAUSS HAUER & FELD

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $60,000 income · posted Jul 20, 2026

View → Q1

AKIN GUMP STRAUSS HAUER & FELD

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $60,000 income · posted Apr 20, 2026

View → Q4

AKIN GUMP STRAUSS HAUER & FELD

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $50,000 income · posted Jan 20, 2026

View → RR

AKIN GUMP STRAUSS HAUER & FELD

4th Quarter (Oct 1 - Dec 31) 2025 · posted Oct 23, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.